A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1500 participants.
Also called NCT05872269
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,500 participants
- Sponsor
- Registry
-
NCT05872269
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- India
- Registry status
- Unknown status
Technical summary
Registry record NCT05872269. Allocation not applicable; no masking; primary purpose treatment. Start 2023-07-20 (actual); primary completion 2025-01-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
- Condition
- NAFLD
- Condition
- Obesity
- Condition
- Type 2 Diabetes
- Condition
- Dyslipidemias
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Saroglitazar
- Lead sponsor
- Zydus Lifesciences Limited
Record details
- Record id
cardio:ct-nct05872269- Content hash
09729b785b90129f3bcbf9198f11bb0d21c164dee545e04be87f7d1e6d9cf97d